Equities

Eom Pharmaceutical Holdings Inc

IMUC:PKL

Eom Pharmaceutical Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1979
  • Today's Change0.00 / 0.00%
  • Shares traded392.00
  • 1 Year change-15.79%
  • Beta0.2568
Data delayed at least 15 minutes, as of May 01 2024 14:43 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their portfolio: EOM613 and EOM147. EOM613 is an investigational immunomodulator. EOM613 is a peptide-nucleic acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. EOM613 helps to suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells resulting in either further activation or suppression. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM147 affects multiple angiogenic growth factors such as VEGF, PdGF, and bFGF.

  • Revenue in USD (TTM)0.00
  • Net income in USD-4.93m
  • Incorporated1987
  • Employees3.00
  • Location
    Eom Pharmaceutical Holdings Inc30721 Russell Ranch Road, Suite 140WESTLAKE VILLAGE 91362United StatesUSA
  • Phone+1 (818) 264-2300
  • Fax+1 (302) 655-5049
  • Websitehttps://imuc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alaunos Therapeutics Inc5.00k-35.14m20.66m1.00--3.28--4,131.22-2.20-2.200.00030.39390.0001--2.005,000.00-96.01-74.83-149.28-89.57-----702,800.00-10,508.06---14.830.00---99.83-49.086.86---15.56--
Context Therapeutics Inc0.00-23.96m21.71m5.00--1.83-----1.50-1.500.000.74350.00----0.00-88.71---102.79--------------0.00-------61.53------
TherapeuticsMD Inc1.30m-7.70m21.74m1.00--0.7422--16.70-0.7466-1.000.12492.540.0195----1,302,000.00-11.51-53.35-19.23-111.61100.0086.67-591.32-236.57----0.00---98.14-39.53-816.85------
Sol Gel Technologies Ltd1.55m-27.24m21.78m36.00--0.5637--14.02-1.02-1.020.05741.390.0338--0.377443,166.67-59.27-31.60-64.80-35.49-----1,752.77-135.76----0.00---59.9864.50-82.52---33.78--
Neurosense Therapeutics Ltd0.00-11.28m21.84m16.00---------0.7625-0.76250.00-0.12190.00----0.00-207.24---395.72----------------------8.59------
Flora Growth Corp76.07m-47.36m21.92m97.00--2.39--0.2882-6.62-7.9710.040.71671.456.7631.13784,237.10-89.22---130.91--23.32---61.35--0.7897--0.2317--127.75---1.87------
Zivo Bioscience Inc27.65k-7.78m21.94m8.00------793.61-4.62-4.620.0163-0.92590.0206----3,456.25-580.66-376.60----41.99---28,127.23-96,315.32---97.39--------11.07------
Synlogic Inc3.37m-57.28m22.13m6.00--0.4092--6.56-11.41-11.410.65814.640.0362----561,833.30-61.46-40.57-74.45-43.82-----1,699.26-3,245.93----0.00009--185.685.9913.40---48.05--
Serina Therapeutics Inc142.00k-14.80m22.26m4.00--1.76--156.74-13.72-13.720.13165.070.0187--4.6635,500.00-194.80-194.46----71.8385.80-10,430.28-2,347.36---2.030.4489--317.65-36.69-41.49------
Eom Pharmaceutical Holdings Inc0.00-4.93m22.42m3.00---------0.0435-0.04350.00-0.0212------0.00---126.34---171.37------------7.41-------254.37------
NRX Pharmaceuticals Inc0.00-30.16m22.86m2.00---------2.95-2.950.00-0.13980.00-------182.00-120.57---168.40--------------------24.14------
Biora Therapeutics Inc4.00k-124.33m23.04m58.00------5,759.36-8.57-8.560.0003-4.280.00009--0.004868.97-293.45-122.84---369.01-----3,108,350.00-415.10---------98.69-87.44-154.63---53.68--
Qilian International Holding Group Ltd46.47m-7.78m23.24m298.00--0.543--0.50-0.2176-0.21761.301.200.80276.4533.30155,944.60-14.032.71-16.843.863.7711.66-17.482.724.43-0.48120.010726.11-28.35-1.60-822.64--12.86--
Lisata Therapeutics Inc0.00-20.84m23.70m25.00--0.483-----2.58-2.580.005.910.00----0.00-32.63-45.97-36.16-50.47------------0.00------61.57------
Polypid Ltd0.00-23.87m23.99m59.00---------19.44-19.440.00-1.270.00----0.00-115.45-76.92-187.15-89.61-----------24.611.25------39.67---42.34--
Vincerx Pharma Inc0.00-40.16m24.37m42.00--1.70-----1.89-1.890.000.52420.00----0.00-103.63---128.01--------------0.00------36.24------
Data as of May 01 2024. Currency figures normalised to Eom Pharmaceutical Holdings Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.